Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0027796
Disease: Neuralgia
Neuralgia 		0.010 GeneticVariation phenotype BEFREE A functional polymorphism in the ABCB1 transporter predicts pharmacologic response to combination of nortriptyline and morphine in neuropathic pain patients. 31738228 2020
CUI: C0034069
Disease: Pulmonary Fibrosis
Pulmonary Fibrosis 		0.010 Biomarker disease BEFREE Here we investigate the expression of two ABC transporters, P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), in human IPF lung tissue and two different bleomycin-induced mouse models of pulmonary fibrosis. 31419911 2020
CUI: C0040479
Disease: Torsades de Pointes
Torsades de Pointes 		0.010 Biomarker disease BEFREE Although used clinically for the treatment of malaria, arrhythmia, and pseudobulbar effect, quinidine can induce acquired long QT syndrome and torsade de pointes through its interaction with the Purkinje fibers, which hinders its clinical application as a P-gp inhibitor. 31770573 2020
CUI: C0553694
Disease: Oropharyngeal disorders
Oropharyngeal disorders 		0.010 AlteredExpression group BEFREE However, murine lungs expressed increased levels of P-gp and BCRP after oropharyngeal and subcutaneous bleomycin administration. 31419911 2020
CUI: C1333064
Disease: Classical Hodgkin's Lymphoma
Classical Hodgkin's Lymphoma 		0.010 Biomarker disease BEFREE We developed two BV-resistant HL cell line models using a pulsatile approach and observed that resistance to BV is associated with an upregulation of multidrug resistance-1 (MDR1). 31811017 2020
CUI: C1800706
Disease: Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis 		0.010 Biomarker disease BEFREE Functionally, this effect reduced murine lung exposure to nintedanib, an FDA-approved IPF therapy known to be a P-gp substrate. 31419911 2020
CUI: C2347747
Disease: Adult Classical Hodgkin Lymphoma
Adult Classical Hodgkin Lymphoma 		0.010 Biomarker disease BEFREE We developed two BV-resistant HL cell line models using a pulsatile approach and observed that resistance to BV is associated with an upregulation of multidrug resistance-1 (MDR1). 31811017 2020
CUI: C2732979
Disease: Acquired long QT syndrome
Acquired long QT syndrome 		0.010 Biomarker disease BEFREE Although used clinically for the treatment of malaria, arrhythmia, and pseudobulbar effect, quinidine can induce acquired long QT syndrome and torsade de pointes through its interaction with the Purkinje fibers, which hinders its clinical application as a P-gp inhibitor. 31770573 2020
CUI: C0007787
Disease: Transient Ischemic Attack
Transient Ischemic Attack 		0.010 GeneticVariation disease BEFREE To investigate the association between ABCB1 polymorphisms and clopidogrel efficacy for minor stroke or TIA. 30742211 2019
CUI: C0010418
Disease: Cryptosporidiosis
Cryptosporidiosis 		0.010 Biomarker disease BEFREE Furthermore, a hollow fiber model of Cryptosporidium infection replicated the in vivo impact of P-glycoprotein on anti-Cryptosporidium efficacy. 31180118 2019
CUI: C0011615
Disease: Dermatitis, Atopic
Dermatitis, Atopic 		0.010 AlteredExpression disease BEFREE Gene expression of P-gp and BCRP was reduced in oxazolone-treated skin and the skin of patients with atopic dermatitis or psoriasis. 31512001 2019
CUI: C0013146
Disease: Drug abuse
Drug abuse 		0.010 Biomarker group BEFREE Junior residents (PGY-1) were more likely to experience abuse than senior residents (PGY-2 and PGY-3; p< .01). 27102995 2019
CUI: C0013595
Disease: Eczema
Eczema 		0.010 AlteredExpression disease BEFREE Gene expression of P-gp and BCRP was reduced in oxazolone-treated skin and the skin of patients with atopic dermatitis or psoriasis. 31512001 2019
CUI: C0014070
Disease: Encephalomyelitis
Encephalomyelitis 		0.010 Biomarker disease BEFREE Collectively, our findings implicate that P-gp inhibitor can promote the therapeutic efficacy of ASIV on EAE mice, which may boost its clinical usage together with ASIV in the therapy of MS. 30717494 2019
CUI: C0014457
Disease: Eosinophilia
Eosinophilia 		0.010 AlteredExpression disease BEFREE Recent studies have associated osteitis with nasal polyps and tissue eosinophilia with the increase in periostin expression and P-glycoprotein mucosal expression. 30874957 2019
CUI: C0025517
Disease: Metabolic Diseases
Metabolic Diseases 		0.010 Biomarker group BEFREE These findings demonstrate for the first time that fenofibrate decreases both mRNA and protein amount of P-gp and suggest that fenofibrate could affect bioavailability and interaction of drugs used to treat dyslipidemia-induced metabolic disorders. 30787874 2019
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis 		0.010 Biomarker disease BEFREE Collectively, our findings implicate that P-gp inhibitor can promote the therapeutic efficacy of ASIV on EAE mice, which may boost its clinical usage together with ASIV in the therapy of MS. 30717494 2019
CUI: C0085281
Disease: Addictive Behavior
Addictive Behavior 		0.010 Biomarker phenotype BEFREE Sequentially, we looked into the detail of (1) the addiction to cocaine and fentanyl by binding to the dopamine transporter and the μ opioid receptor (DAT and μOR, respectively), (2) the potential drug-drug interaction of cocaine and fentanyl via p-glycoprotein (P-gp) efflux, (3) the metabolism of cocaine and fentanyl in CYP3A4, and (4) the physiologically based pharmacokinetic (PBPK) model for two drugs and their drug-drug interaction at the absorption, distribution, metabolism, and excretion (ADME) level. 31257858 2019
CUI: C0085437
Disease: Meningitis, Bacterial
Meningitis, Bacterial 		0.010 AlteredExpression group BEFREE This observation was correlated to decreased P-gp expression both in vitro and during infection in vivo using a mouse model of bacterial meningitis. 31434575 2019
CUI: C0085605
Disease: Liver Failure
Liver Failure 		0.010 AlteredExpression disease BEFREE Liver failure altered P-glycoprotein (P-gp) function and expression at blood-brain barrier (BBB), partly owing to hyperammonemia. 30639310 2019
CUI: C0149871
Disease: Deep Vein Thrombosis
Deep Vein Thrombosis 		0.010 GeneticVariation disease BEFREE The ABCB1 polymorphism rs1045642 demonstrated statistical significance, albeit only in premenopausal patients, i.e. the effect of two variant alleles on the TTE extension was demonstrated only in the premenopausal group (p=0.0012, HR 0.69; 95% CI 0.21-2.31), and statistical significance (p=0.0106) only for gynaecological/vasomotor AEs (p=0.0221, HR=1.0588), with no evidence of any influence on the incidence and onset of venous complications (i.e. deep venous thrombosis or pulmonary embolism). 29135105 2019
CUI: C0206667
Disease: Adrenal Cortical Adenoma
Adrenal Cortical Adenoma 		0.010 AlteredExpression disease BEFREE MDR1 mRNA and P-gp protein expression were lower in ACCs compared to adrenocortical adenomas (P<0.0001; P<0.01, respectively). 30650062 2019
CUI: C0220994
Disease: Hyperammonemia
Hyperammonemia 		0.010 AlteredExpression phenotype BEFREE Increase in P-glycoprotein levels in the blood-brain barrier of partial portal vein ligation /chronic hyperammonemia rats is medicated by ammonia/reactive oxygen species/ERK1/2 activation: In vitro and in vivo studies. 30639310 2019
CUI: C0235162
Disease: Difficulty sleeping
Difficulty sleeping 		0.010 Biomarker phenotype BEFREE Poor sleep quality is similar between early residency cohorts (PGY-1) and later residency cohorts (PGY-3+). 31757438 2019
CUI: C0278874
Disease: Adult Ependymoma
Adult Ependymoma 		0.010 Biomarker disease BEFREE ABCB1 is a predictive marker of chemotherapy response in ependymoma patients and vardenafil, currently used to treat paediatric pulmonary hypertension in children, could be repurposed to reduce chemoresistance, migration and invasion in paediatric ependymoma patients at non-toxic concentrations. 31311995 2019